Update re AbC-19TM Rapid Test
Omega Diagnostics Gp (ODX.L) Update re AbC-19 Rapid Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes today’s update from Abingdon Health plc (AIM: ABDX)
Omega Diagnostics Group PLC (ODX.L) Mologic CE Mark Rapid Antigen Test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, welcomes the news that Mologic Ltd (“Mologic”) has received CE Mark for it’s professional-use COVID-19
Omega Diagnostics Gp (ODX.L) UK-RTC Update
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, notes the press release issued today by the UK Rapid Test Consortium (“UK-RTC”), of which
Omega Diagnostics Gp (ODX.L) Chinese approval for Food Detective® test
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that the National Medical Products Administration (“NMPA”), formerly the China Food and Drug Administration,
Omega Diagnostics Gp (ODX.L) Trading update and notice of interim results
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces the following trading update in advance of releasing its interim results for the six
Omega Diagnostics Gp (ODX.L) Notice of Trading Update and Investor Presentation
Omega (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance, announces that it will release a trading update for the six months ended 30 September
Omega Diagnostics Gp (ODX.L) UK-RTC contract for the Supply of Goods
Agreed terms for the supply of goods by consortium members to fulfil UK Government orders Agreement also extends to the supply of other third-party customers, if permitted
Open Orphan PLC (ORPH.L) Launch of Covid-19 Antibody Testing
Open Orphan plc (ORPH), a rapidly growing specialist CRO pharmaceutical services company which is the world leader in the testing of vaccines and antivirals using human challenge study models, announces